The Committee for Medicinal Products for Human Use (CHMP) has published the highlights of its most recent meeting held on 20th- 23rd March 2017.
Six medicines were recommended for approval, including three with orphan designations. One of the orphans, Dinutuximab beta Apeiron (dinutuximab beta) for the treatment of high-risk neuroblastoma, was recommended for a marketing authorisation granted under exceptional circumstances.
Please click here to see the summary with the full list of recommendations for approval, positive opinions and withdrawals.
Key figures from the March 2017 CHMP meeting are represented in the graphic below.